ArticleNature2018
Codon-specific translation reprogramming promotes resistance to targeted therapy.
Erratum issuedAbstract read
In one paragraph
Article in Nature, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 192 papers.
0numbers the graph read from it
0cells of the map it votes in
192citing papers in PubMed
11.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
192 citing papers in PubMed, 262 citations in OpenAlex.
- Genome-wide CRISPR screen identifies ELP5 as a determinant of gemcitabine sensitivity in gallbladder cancer.Nature communications · 2019Trial
- The role of RNA modifications in cancer translational control.RNA biology · 2026Review
- METTL1-mediated m7G modification of valine tRNAs drives metabolic adaptation in pancreatic ductal adenocarcinoma cells.The Journal of clinical investigation · 2026Article
- Mechanisms and therapeutic opportunities of the ribotoxic stress response in cancer.Molecular oncology · 2026Review
- Selective mRNA translation determines adaptative mutability of melanoma cells to anti-BRAF/MEK combination therapy.EMBO molecular medicine · 2026Article
- Rare Biallelic CTU2 Variants in an Individual With CAKUT: Clinical Characterization and Minigene Splicing Analysis.Molecular genetics & genomic medicine · 2026Article
- Ribosome biogenesis and selective translational control as oncogenic vulnerabilities in hematologic malignancies.Molecular cancer · 2026Review
- The translation landscape of ovarian clear cell carcinoma indicates that RBM4 plays a pro-oncogenic role in tumor progression.Oncogene · 2026Article
- Family-Based Study RevealsInternational journal of molecular sciences · 2026Article
- Elp3 uses a conserved molecular tunnel to transport acetate between distant active sites and catalyze tRNA wobble base modification.Nature communications · 2026Article
- Metal-dependent regulated cell death: Molecular architecture and translational frontiers.iMeta · 2026Review
- G/C-ending and synonymous codon bias define functional translational programs that shape human tissue and cancer proteomes.NAR genomics and bioinformatics · 2026Article
- TRMT6/61A-mediated tRNA m1A methylation promotes codon-dependent TAB2 translation and drives AML progression.Molecular medicine (Cambridge, Mass.) · 2026Article
- RNA modifications in cancer and their detection: a review.Japanese journal of clinical oncology · 2026Review
- Mathematical modeling of ribosome competition informs testable treatment strategies for drug-tolerant cancer persister cells.iScience · 2026Article
- tRNA modifications in cancer: from molecular mechanisms to clinical translation.Biomarker research · 2026Review
- Unbiased profiling of translational landscape reveals TNFR2 as a translation-dependent vulnerability in colorectal cancer.Journal of experimental & clinical cancer research : CR · 2026Article
- mAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Disruption of tRNA threonylation triggers RIG-I mediated anti-tumour immune response.Nature communications · 2026Article
- Targeting tRNA-Arg-TCT-4-1 suppresses cancer cell growth and tumorigenesis.bioRxiv : the preprint server for biology · 2026Article
132 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
29 authors at 7 institutions in 3 countries.
Francesca RapinoLaboratory of Cancer Signaling, University of Liège, Liège, Belgium.
Sylvain DelaunayLaboratory of Cancer Signaling, University of Liège, Liège, Belgium.
Florian RambowLaboratory for Molecular Cancer Biology, Department of Oncology, KU Leuven, Leuven, Belgium.
Zhaoli ZhouLaboratory of Cancer Signaling, University of Liège, Liège, Belgium.
Lars TharunInstitute for Pathology, University Hospital Cologne, Cologne, Germany.
Pascal De TullioCentre for Interdisciplinary Research on Medicines (CIRM), University of Liège, Liège, Belgium.
Olga SinMax Planck Research Group for RNA Biology, Max Planck Institute for Molecular Biomedicine, Münster, Germany.
Kateryna ShostakGIGA-institute, University of Liège, Liège, Belgium.
Sebastian SchmitzLaboratory of Cancer Signaling, University of Liège, Liège, Belgium.
Jolanda PiepersDepartment of Radiotherapy (MAASTRO)/GROW, School for Developmental Biology and Oncology, Maastricht University, Maastricht, The Netherlands.
Bart GhesquièreMetabolomics Core Facility, Center for Cancer Biology, VIB, Leuven, Belgium.
Latifa KarimGIGA-institute, University of Liège, Liège, Belgium.
Benoit CharloteauxGIGA-institute, University of Liège, Liège, Belgium.
Diane JamartLaboratory of Cancer Signaling, University of Liège, Liège, Belgium.
Alexandra FlorinInstitute for Pathology, University Hospital Cologne, Cologne, Germany.
Charles LambertGIGA-institute, University of Liège, Liège, Belgium.
Andrée RoriveMedical Oncology, CHU Sart Tilman Liège, University of Liège, Liège, Belgium.
Guy JerusalemMedical Oncology, CHU Sart Tilman Liège, University of Liège, Liège, Belgium.
Eleonora LeucciLaboratory for Molecular Cancer Biology, Department of Oncology, KU Leuven, Leuven, Belgium.
Michael DewaeleLaboratory for Molecular Cancer Biology, Department of Oncology, KU Leuven, Leuven, Belgium.
Marc VooijsDepartment of Radiotherapy (MAASTRO)/GROW, School for Developmental Biology and Oncology, Maastricht University, Maastricht, The Netherlands.
Sebastian A LeidelMax Planck Research Group for RNA Biology, Max Planck Institute for Molecular Biomedicine, Münster, Germany.
Michel GeorgesGIGA-institute, University of Liège, Liège, Belgium.
Marianne VozGIGA-institute, University of Liège, Liège, Belgium.
Bernard PeersGIGA-institute, University of Liège, Liège, Belgium.
Reinhard BüttnerInstitute for Pathology, University Hospital Cologne, Cologne, Germany.
Jean-Christophe MarineLaboratory for Molecular Cancer Biology, Department of Oncology, KU Leuven, Leuven, Belgium.
Alain ChariotGIGA-institute, University of Liège, Liège, Belgium.
Pierre CloseLaboratory of Cancer Signaling, University of Liège, Liège, Belgium. Pierre.Close@uliege.be.
University of Liège · BEVIB-KU Leuven Center for Cancer Biology · BEUniversity Hospital Cologne · DEMaastricht University · NLMaastro Clinic · NLMax Planck Institute for Molecular Biomedicine · DEUniversity of Münster · DE
Funding
No grant is acknowledged in the PubMed record.
Abstract
Reprogramming of mRNA translation has a key role in cancer development and drug resistance
Indexed as
Protein BiosynthesisAnimalsCarrier ProteinsCell Line, TumorCodonDrug Resistance, NeoplasmFemaleHumansMaleMechanistic Target of Rapamycin Complex 2MelanomaMelanoma, ExperimentalMiceMice, Inbred NODMice, SCIDPhosphorylationCarrier ProteinsCodonElp1 protein, humanMechanistic Target of Rapamycin Complex 2Proto-Oncogene Proteins B-rafRNA, MessengerRNA, TransferTranscriptional Elongation FactorsUridineVemurafenib
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.